Terms: = Breast cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
103 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of pralsetinib in Chinese advanced ret-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
3. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
4. ECL resonance energy transfer-regulated "off-on" mode biosensor for the detection of miRNA-150-5p in triple negative breast cancer.
Zhong W; Liang Z; Zhao H; Wang P; Li Z; Shi J; Ma Q
Biosens Bioelectron; 2023 Nov; 240():115663. PubMed ID: 37678060
[TBL] [Abstract] [Full Text] [Related]
5. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive breast cancers for Targeted treatment.
Kim BJ; Zheng ZY; Lei JT; Holt MV; Chen A; Peng J; Fandino D; Singh P; Kennedy H; Dou Y; Chica-Parrado MDR; Bikorimana E; Ye D; Wang Y; Hanker AB; Mohamed N; Hilsenbeck SG; Lim B; Asirvatham JR; Sreekumar A; Zhang B; Miles G; Anurag M; Ellis MJ; Chang EC
Cancer Res Commun; 2023 Jul; 3(7):1366-1377. PubMed ID: 37501682
[TBL] [Abstract] [Full Text] [Related]
6. Ponatinib: An update on its drug targets, therapeutic potential and safety.
Gao Y; Ding Y; Tai XR; Zhang C; Wang D
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188949. PubMed ID: 37399979
[TBL] [Abstract] [Full Text] [Related]
7. FDA Approval Summary: Selpercatinib for the treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
8. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven breast cancer.
Gou X; Kim BJ; Anurag M; Lei JT; Young MN; Holt MV; Fandino D; Vollert CT; Singh P; Alzubi MA; Malovannaya A; Dobrolecki LE; Lewis MT; Li S; Foulds CE; Ellis MJ
Cancer Res; 2023 Oct; 83(19):3237-3251. PubMed ID: 37071495
[TBL] [Abstract] [Full Text] [Related]
9. High expression of the ret receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Kakati RT; Kim H; Whitman A; Spanheimer PM
Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
[TBL] [Abstract] [Full Text] [Related]
10. GDNF-ret signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1.
Marks BA; Pipia IM; Mukai C; Horibata S; Rice EJ; Danko CG; Coonrod SA
BMC Cancer; 2023 Feb; 23(1):138. PubMed ID: 36765275
[TBL] [Abstract] [Full Text] [Related]
11. Aerobic exercise combined with resistance exercise training improves cardiopulmonary function and blood lipid of patients with breast cancer: A systematic review and meta-analysis.
Kong L; Gao R
Medicine (Baltimore); 2022 Dec; 101(51):e32391. PubMed ID: 36595800
[TBL] [Abstract] [Full Text] [Related]
12. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Sivakumar S; Jin DX; Tukachinsky H; Murugesan K; McGregor K; Danziger N; Pavlick D; Gjoerup O; Ross JS; Harmon R; Chung J; Decker B; Dennis L; Frampton GM; Molinero L; Oesterreich S; Venstrom JM; Oxnard GR; Hegde PS; Sokol ES
Nat Commun; 2022 Dec; 13(1):7495. PubMed ID: 36470901
[TBL] [Abstract] [Full Text] [Related]
13. JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.
Das P; Gupta A; Desai KV
Front Endocrinol (Lausanne); 2022; 13():1028616. PubMed ID: 36419768
[TBL] [Abstract] [Full Text] [Related]
14. Integration of Universal Germline Genetic Testing for All New breast cancer Patients.
Culver JO; Freiberg Y; Ricker C; Comeaux JG; Chang EY; Banerjee V; Sturgeon D; Solomon I; Kagey J; Dobre MG; Carey J; Carr A; Cho S; Lu J; Kang IM; Patel K; Terando A; Ye JC; Li M; Lerman C; Spicer D; Nelson M
Ann Surg Oncol; 2023 Feb; 30(2):1017-1025. PubMed ID: 36161375
[TBL] [Abstract] [Full Text] [Related]
15. Super-enhancer-controlled positive feedback loop BRD4/ERα-ret-ERα promotes ERα-positive breast cancer.
Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
[TBL] [Abstract] [Full Text] [Related]
16. An integrative pan cancer analysis of ret aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
17. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
18. Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent.
Jung M; Lee KM; Im Y; Seok SH; Chung H; Kim DY; Han D; Lee CH; Hwang EH; Park SY; Koh J; Kim B; Nikas IP; Lee H; Hwang D; Ryu HS
Mol Oncol; 2022 May; 16(9):1795-1815. PubMed ID: 35278276
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive immunohistochemical analysis of ret, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.
Pavanelli AC; Mangone FR; Yoganathan P; Bessa SA; Nonogaki S; de Toledo Osório CAB; de Andrade VP; Soares IC; de Mello ES; Mulligan LM; Nagai MA
Breast Cancer Res Treat; 2022 Feb; 192(1):43-52. PubMed ID: 35031902
[TBL] [Abstract] [Full Text] [Related]
20. How does nintedanib overcome cancer drug-resistant mutation of ret protein-tyrosine kinase: insights from molecular dynamics simulations.
Cao S; Jiang X; Tan C; Fu M; Xiong W; Ji D; Lv J
J Mol Model; 2021 Nov; 27(11):337. PubMed ID: 34725737
[TBL] [Abstract] [Full Text] [Related]
[Next]
